• Signed the informed consent form (ICF) and able to comply with the visits and related procedures specified in the protocol;

• Aged ≥18 years and ≤75 years, regardless of gender;

• Patients with unresectable advanced, recurrent or metastatic melanoma (excluding uveal melanoma) ;

• Patients who have failed or resisted to PD-1 antibodies；

• Patients must have failed or resisted to at least two frontlines systemic tehrapy(if knowed with BRAF V600 mutate, then need to failed to BRAF/MEK inhibitor; if knowed with NRAS mutate, then need to failed to Tunlametinib) ；

• TILs can be isolated from a surgically resectable tumor region: the tissue volume must be \>150mm3, and the lesion has not received local treatment (such as radiotherapy, radiofrequency ablation, oncolytic virus, etc.) or progressed after local treatment;There are still at least 1 measurable lesion (according to RECIST1.1 criteria ) even after TIL sampling and resection of surgically resectable tissue;

• ECOG performance status 0-1;

• Expected survival time \>3 months;

• With sufficient hematology and end-organ function;

• Good compliance and able to adhere to the study visit plan and other agreement requirements.